Upstream Bio (UPB) Change in Account Payables (2023 - 2026)
Upstream Bio's quarterly Change in Account Payables came in at -$1.0 million in Q1 2026, down 242.9% year-on-year from $711000.0 in Q1 2025, and up 17.13% quarter-over-quarter from -$1.2 million in Q4 2025.
Upstream Bio has reported Change in Account Payables for 4 years, with the latest figure at -$1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 242.9% year-over-year to -$1.0 million; the trailing twelve-month figure through Mar 2026 stood at -$3.0 million (down 189.98% YoY), and the FY2025 full-year result was -$1.3 million, down 163.51% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1.0 million, up from -$1.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $3.7 million in Q2 2024, with the low at -$2.2 million in Q2 2025.
- Average Change in Account Payables over 4 years is $147700.0, with a median of -$394500.0 recorded in 2024.
- Year-over-year, Change in Account Payables surged 905.17% in 2025 and plunged 242.9% in 2026.
- Tracing UPB's Change in Account Payables over 4 years: stood at $1.8 million in 2023, then sank by 149.57% to -$871000.0 in 2024, then sank by 40.76% to -$1.2 million in 2025, then climbed by 17.13% to -$1.0 million in 2026.
- The last three Change in Account Payables figures came in at -$1.0 million (Q1 2026), -$1.2 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | -1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.02 Mn |
| Mar 31, 2026 | -1.02 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | 711,000.00 |
| Mar 31, 2025 | 711,000.00 |
| Dec 31, 2024 | -871,000.00 |
| Dec 31, 2024 | -871,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Jun 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 3.68 Mn |
| Mar 31, 2024 | -615,000.00 |
| Mar 31, 2024 | -615,000.00 |
| Dec 31, 2023 | 1.76 Mn |
| Dec 31, 2023 | 1.76 Mn |